Adult pneumococcal vaccination guideline

South African Medical Journal

Volumn 89, Issue 11 II, 1999, Pages 1222-1230

  Feldman, C ^a   Klugman, K ^a  

^a Centre for Quality Care   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; PNEUMOCOCCUS VACCINE;

ADULT; AGE; ANAPHYLAXIS; ANTIBODY TITER; ARTICLE; BACTERICIDAL ACTIVITY; COST EFFECTIVENESS ANALYSIS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; PHAGOCYTE; PHAGOCYTOSIS; PNEUMONIA; PRACTICE GUIDELINE; SEROTYPE; SOUTH AFRICA; STREPTOCOCCUS INFECTION; VACCINATION;

ADOLESCENT; ADULT; AGED; BACTERIAL VACCINES; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, MICROBIAL; HUMANS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 0343049049     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Centers for Disease Control and Prevention (CDC). Pneumonia and influenza death rates -United States, 1979 - 1994. MMWR 1995; 44: 535-537.
2. Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997; 46(RR-8): 1-24.
3. Crewe-Brown HH, Karstaedt AS, Saunders GL, et al. Streptococcus pneumoniae blood culture isolates from patients with and without human immunodeficiency virus infection: Alterations in penicillin susceptibilities and in serogroups or serotypes. Clin Infect Dis 1997; 25: 1165-1172.
4. Department of National Health and Population Development. Epidemiological Comments 1994; 21: 68-75.
5. Dumyati G, Treanor JJ. Practical use of vaccines to prevent infection with influenza virus and Streptococcus pneumoniae. Clin Immunother 1994; 2: 248-260.
6. Farr BM, Johnston BL, Cobb DK, et al. Preventing pneumococcal bacteremia in patients at risk. Arch Intern Med 1995; 155: 2336-2340.
7. Fedson DS. Improving the use of pneumococcal vaccine through a strategy of hospital-based immunization. A review of its rationale and implications. J Am Geriatr Soc 1985; 33: 142-150.
8. Fedson DS. Influenza and pneumococcal immunization strategies for physicians. Chest 1987; 91: 436-443.
9. Fedson DS, Musher DM. Pneumococcal vaccine. In: Fiotkin SA, Mortimer EA, eds. Vaccines. Philadephia: WB Saunders, 1994: 517-564.
10. Friedland IR, Klugman KP. Advances in the management of penicillin-resistant pneumococcal meningitis. S Afr Med J 1992; 81: 341-342.
11. Janoff EN, Rubins JB. Invasive pneumococcal disease in the immunocompromised host. Microbial Drug Resistance 1997; 3: 215-232.
12. Jones N, Huebner R, Khoosal M, et al. The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population. AIDS 1998; 12: 2177-2184.
13. Obaro SK, Monteil MA, Henderson DC. The pneumococcal problem. BMJ 1998; 312:1521-1525.
14. Peetermans W, Bachez P, Peleman R, et al. Belgian consensus on pneumococcal vaccine. Acta Clinica Belgica 1996; 51-5: 350-356.
15. Wong CA, Macfarlane JT. Prevention of community-acquired pneumococcal and influenza infection in adults: a re-evaluation of vaccination. Eur Respir Mon 1997; 3: 56-81.
16. Musher MD. Streptococcus pneumoniae. In: Principles and Practice of Infectious Diseases. Mandell, GL, Bennett JE, Kolin RL, eds. 4th ed. New York: Churchill-Livingstone, 1995: 1811-1826.
17. Feldman C, Kallenbach JM, Miller SD, Thorburn JR, Koornhof HJ. Community-acquired pneumonia due to penicillin-resistant pneumococci. N Engt J Med 1985; 313: 615-617.
18. Feldman C, Klugman K. Antibiotic-resistant pneumococcal pneumonia. S Afr Med J 1996; 86: 28-30.
19. Friedland IR, McCracken GH. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994; 331: 377-382.
20. Jacobs MR, Koornhof HJ, Robins-Brown RM, et al. Emergence of multiply resistant pneumococci. N Engl J Med 1978; 299: 735-740.
21. Klugman KP. Pneumococcal resistance to antibiotics. Clin Microbiol Rev 1990; 3: 171-196.
22. Klugman KP, Feldman C. The clinical relevance of antibiotic resistance in the management of pneumococcal pneumonia. Infectious Disease in Clinical Practice 1998; 7: 180-184.
23. Nuorti JP, Butler JC, Crutcher JM, et al. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. N Engl J Med 1998; 338: 1861-1868.
24. Oppenheim B, Koornhof HJ, Austrian R. Antibiotic-resistant pneumococcal disease in children at Baragwanath Hospital, Johannesburg. Pediatr Infect Dis 1986; 5: 520-524.
25. Pallares R, Gudiol F, Liñares J, et al. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. N Engl J Med 1987; 317: 18-22.
26. Pallares R, Liñares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333: 474-480.
27. Vondracek TG, Pham, TP, Huycke MM. A hospital-based pharmacy intervention program for pneumococcal vaccination. Arch Intern Med 1998; 158: 1543-1547.
28. Ward J, Koornhof H. Antibiotic-resistant pneumococci. Current Clinical Topics in Infectious Diseases 1980; 1: 265-286.
29. Burman LA, Norrby R, Trollfors B. Invasive pneumococcal infections: Incidence, predisposing factors, and prognosis. Rev Infect Dis 1985; 7: 133-142.
30. Kaufman P. Pneumonia in old age. Arch Intern Mat 1947; 79: 518-531.
31. Konradsen HB. Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons. Clin Infect Dis 1995; 21: 616-620.
32. Lipsky BA, Boyko EJ, Inui TS, et al. Risk factors for acquiring pneumococcal infections. Arch Intern Med 1986; 146: 2179-2185.
33. Musher MD. Pneumococcal outbreaks in nursing homes. N Engl J Med 1998; 338: 1915-1916.
34. Smith FE, Palmer DL. Alcoholism, infection and altered host defense. A review of clinical and experimental observations. J Chron Dis 1976; 29: 35-49.
35. Feldman C, Sacho H, Levy H, Kallenbach JM, Koornhof HJ. Pneumococcal bacteraemia in adults in a low socio-economic urban population. Q J Med 1998; 69: 961-971.
36. Steven N, Wright P. Pneumococcal immunisation and the healthy elderly. Lancet 1992; 340: 1036-1037.
37. Feldman C, Glatthaar M, Morar R, et at. Bacteremic pneumococcal pneumonia in HIV-seropositive and HIV-seronegative adults. Chest 1999; 116: 107-114.
38. Brown PD, Lerner SA. Community-acquired pneumonia. Lancet 1998; 352: 1295-1302.
39. Feldman C, Kallenbach JM, Levy H, et al. Community-acquired pneumonia of diverse aetiology: prognostic features in patients admitted to an intensive care unit and a "severity of illness" score. Intensive Care Med 1989; 15: 302-307.
40. Feldman C, Ross S, Goolam Mahomed A, Omar J, Smith C. The aetiology of severe community-acquired pneumonia and its impact on initial, empiric, antimicrobial chemotherapy. Respir Med 1995; 89: 187-192.
41. Potgieter PD, Hammond JMJ. Etiology and diagnosis of pneumonia requiring ICU admission. Chest 1992; 101: 199-203.
42. Prout S, Potgieter PD, Forder AA, Moodie JW, Matthews J. Acute community-acquired pneumonia. S Afr Med J 1983; 64: 443-446.
43. American College of Physicians. Health and Public Policy Committee. Pneumococcal vaccine. Ann Intern Med 1986; 104: 118-120.
44. Shann F. Modern vaccines. Pneumococcus and influenza. Lancet 1990; 335: 898-901.
45. Ahonkhai VI, Landesman SH, Fikrig SM, et al. Failure of pneumococcal vaccine in children with sickle-cell disease. N Engl J Med 1979; 301: 26-27.
46. Amman AJ, Addiego J, Wara DW, Lubin B, Smith WB, Mentzer WC. Polyvalent pneumococcal-polysaccharide immunization of patients with sickle-cell anemia and patients with splenectomy. N Engt J Med 1977; 297: 987-900.
47. Davidson M, Bulkow MS, Grabman J, et al. Immunogenicity of pneumococcal revaccination in patients with chronic disease. Arch Intern Med 1994; 154: 2209-2214.
48. Fuchshuber A, Kühnemund O, Keuth B, Lütticken R, Michalk D, Querfeld U. Pneumococcal vaccine in children and young adults with chronic renal disease. Nephrol Dial Transplant 1996; 11: 468-473.
49. Giebink GS, Foker JE, Kim Y, Schiffman G. Serum antibody and opsonic responses to vaccination with pneumococcal capsular polysaccharide in normal and splenectomized children. J Infect Dis 1980; 141: 404-412.
50. Hedlund JU, Kalin ME, Ortqvist AB, Henrichsen J. Antibody response to pneumococcal vaccine in middle-aged and elderly patients recently treated for pneumonia. Arch Intern Med 1994; 154: 1961-1965.
51. Hilleman MR, Carlson AJ, McLean AA, et al. Streptococcus pneumoniae polysaccharide vaccine: Age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines. Rev Infect Dis 1981; 3 (suppl): S31-S42.
52. Musher DM, Luchi MJ, Watson DA, Hamilton R, Baughn RE. Pneumococcal polysaccharide vaccine in young adults and older bronchitics determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide. J Infect Dis 1990; 161: 728-735.
53. Rodriguez-Barradas MC, Musher DM, Lahart C, et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumucoccal vaccine. J Infect Dis 1992; 165: 553-556.
54. Sankilampi U, Honkanen PO, Bloigu A, Herva E, Leinonen M. Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis 1996; 173: 387-393.
55. Austrian R, Douglas RM, Schiffman G, et al. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Phys 1976; 89: 184-194.
56. Bolan G, Broome CV, Facklam RR, et al. Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med 1986; 104: 1-6.
57. Broome CV. Efficacy of pneumococcal polysaccharide vaccines. Rev Infect Dis 1981; 3: suppl, S82-S96.
58. Fedson DS, Shapiro ED, LaForce FM, et al. Pneumococcal vaccine after 15 years of use Another view. Arch Intern Med 1994; 154: 2531-2535.
59. Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994; 154: 2666-2677.
60. Forrester HL, Jahnigen DW, LaForce FM. Inefficacy of pneumococcal vaccine in a high-risk population. Am J Med 1987; 83: 425-430.
61. MacLeod CM, Hodges RG, Heidelberger M, Bernhard WG. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med 1945; 82: 445-465.
62. Örtqvist, A, Hedlund J, Burman L-A, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 1998; 351: 399-403.
63. Riley ID, Tarr PI, Andrews M, et al. Immunisation with a polyvalent pneumococcal vaccine. Lancet 1977; i: 1338-1341.
64. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325: 1453-1460.
65. Shapiro ED, Clemens JD. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med 1984; 101: 325-330.
66. Simberkoff MS, Cross AP, Al-Ibrahim M, et al. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 315: 1318-1327.
67. Sims RV, Steinmann WC, McConville JH, et al. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988; 108: 653-657.
68. Smith P, Oberholzer D, Hayden-Smith S, et al. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 1977; 238: 2613-2616.
69. Ammann AJ. Current status of pneumococcal polysaccharide immunization in patients with sickle cell disease or impaired splenic function. American Journal of Pediatric Hematology/Oncology 1982; 4: 301-306.
70. Falletta JM, Woods GM, Verter JI et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. J Pediatr 1995; 127: 685-690.
71. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 1986; 314: 1593-1599.
72. Morbidity and Mortality Weekly Review. Outbreaks of pneumococcal pneumonia among unvaccinated residents in chronic-care facilities - Massachusetts, October 1995, Oklahoma, February 1996, and Maryland, May-June 1996. MMWR 1997; 46: 60-62.
73. Rutherford EJ, Livengood J, Higginbotham M, et al. Efficacy and safety of pneumococcal revaccination after splenectomy for trauma. J Trauma 1995; 39: 448-452.
74. Styrt BA. Risks of infection and protective strategies for the asplenic patient. Infectious Diseases in Clinical Practice 1996; 5: 94-100.
75. Brichacek B, Swindells S, Janoff EN, Pirruccello S, Stevenson M. Increased plasma human immunodeficiency virus type I burden following antigenic challenge with pneumococcal vaccine. J Infect Dis 1996; 174: 1191-1199.
76. Gilks CF, French N, Nakiyingi J, et al. Lack of efficacy of 23-valent pneumococcal polysaccharide vaccine in HIV-2-infected Ugandan adults. Pneumococcal Vaccines for the World 1998 Conference, Washington, DC, 12 - 14 October 1998.
77. Keller DW, Breiman RF. Preventing bacterial respiratory tract infections among persons infected with human immunodeficiency virus. Clin Infect Dis 1995; 21 (suppl 1): S77-S83.
78. Herman CM, Chen GJ, High KP. Pneumococcal penicillin resistance and the cost-effectiveness of pneumococcal vaccine. Infect Med 1998; 15: 233-275.
79. Makela PH. Cost benefit analysis of pneumococcal vaccination. International Congress and Symposium Series 1995; 210. 41-47.
80. Sisk JE, Moskowitz AJ, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997; 278: 1333-1339.
81. Kayhty H, Eskola J. New vaccines for the prevention of pneumococcal infections. Emerging Infectious Diseases 1996; 2: 289-298.